CERTIFIED PHARMACY BENEFIT SPECIALIST PRACTICE EXAM (SAMPLE)

STUDY GUIDE



SAMPLE STUDY GUIDE WITH LIMITED QUESTIONS

VISIT US ONLINE FOR THE FULL VERSION STUDY GUIDE

https://pharmbenefitspecialist.examzify.com

Copyright © 2026 by Examzify - A Kaluba Technologies Inc. product.

ALL RIGHTS RESERVED.

No part of this book may be reproduced or transferred in any form or by any means, graphic, electronic, or mechanical, including photocopying, recording, web distribution, taping, or by any information storage retrieval system, without the written permission of the author.

Notice: Examzify makes every reasonable effort to obtain accurate, complete, and timely information about this product from reliable sources.

SAMPLE

Table of Contents

Copyright 1

Table of Contents 2

Introduction 3

How to Use This Guide 4

Questions 5

Answers 8

Explanations 10

Next Steps 16

SAMPLE

Introduction

Preparing for a certification exam can feel overwhelming, but with the right tools, it becomes an opportunity to build confidence, sharpen your skills, and move one step closer to your goals. At Examzify, we believe that effective exam preparation isn't just about memorization, it's about understanding the material, identifying knowledge gaps, and building the test-taking strategies that lead to success.

This guide was designed to help you do exactly that.

Whether you're preparing for a licensing exam, professional certification, or entry-level qualification, this book offers structured practice to reinforce key concepts. You'll find a wide range of multiple-choice questions, each followed by clear explanations to help you understand not just the right answer, but why it's correct.

The content in this guide is based on real-world exam objectives and aligned with the types of questions and topics commonly found on official tests. It's ideal for learners who want to:

- Practice answering questions under realistic conditions,
- Improve accuracy and speed,
- Review explanations to strengthen weak areas, and
- Approach the exam with greater confidence.

We recommend using this book not as a stand-alone study tool, but alongside other resources like flashcards, textbooks, or hands-on training. For best results, we recommend working through each question, reflecting on the explanation provided, and revisiting the topics that challenge you most.

Remember: successful test preparation isn't about getting every question right the first time, it's about learning from your mistakes and improving over time. Stay focused, trust the process, and know that every page you turn brings you closer to success.

Let's begin.

SAMPLE

How to Use This Guide

This guide is designed to help you study more effectively and approach your exam with confidence. Whether you're reviewing for the first time or doing a final refresh, here's how to get the most out of your Examzify study guide:

1. Start with a Diagnostic Review

Skim through the questions to get a sense of what you know and what you need to focus on. Your goal is to identify knowledge gaps early.

2. Study in Short, Focused Sessions

Break your study time into manageable blocks (e.g. 30 – 45 minutes). Review a handful of questions, reflect on the explanations.

3. Learn from the Explanations

After answering a question, always read the explanation, even if you got it right. It reinforces key points, corrects misunderstandings, and teaches subtle distinctions between similar answers.

4. Track Your Progress

Use bookmarks or notes (if reading digitally) to mark difficult questions. Revisit these regularly and track improvements over time.

5. Simulate the Real Exam

Once you're comfortable, try taking a full set of questions without pausing. Set a timer and simulate test-day conditions to build confidence and time management skills.

6. Repeat and Review

Don't just study once, repetition builds retention. Re-attempt questions after a few days and revisit explanations to reinforce learning. Pair this guide with other Examzify tools like flashcards, and digital practice tests to strengthen your preparation across formats.

There's no single right way to study, but consistent, thoughtful effort always wins. Use this guide flexibly, adapt the tips above to fit your pace and learning style. You've got this!

SAMPLE

Questions

SAMPLE

1. What is the role of a rebate aggregator?

A. To distribute drugs to pharmacies

B. To manage manufacturer rebate contracts

C. To adjudicate patient claims

D. To create formulary lists

2. What classification of Drug Utilization Review (DUR) evaluates a patient's drug therapy before medication is dispensed?

A. Prospective

B. Concurrent

C. Retrospective

D. Introspective

3. What term describes the complete elimination of hidden cash flows and full disclosure of service revenues?

A. Pass-through

B. Transparency

C. Fiduciary

D. Non-disclosure

4. How does the Affordable Care Act influence pharmacy benefits?

A. It eliminates drug coverage requirements

B. It mandates coverage for preventive medications only

C. It requires health plans to provide essential health benefits

D. It reduces costs for brand-name drugs

5. What is a "spread" in the context of Pharmacy Benefit Managers?

A. The difference between PBM buying price and selling price

B. The total cost of prescription drugs

C. The discount offered by pharmacies to PBMs

D. The rebate amount from drug manufacturers

SAMPLE

6. What type of cancer is Gleevec used to treat?

A. Prostate Cancer

B. Multiple Myeloma

C. Leukemia and Other Types of Cancer

D. Rheumatoid Arthritis

7. Which contracts are the most common pricing arrangements for PBMs with clients?

A. Capitated Contracts

B. Fee-For-Service Contracts

C. Shared Savings Contracts

D. Comprehensive Contracts

8. What is the main difference between generic and brand-name drugs?

A. Generic drugs are sold at higher prices

B. Brand-name drugs are chemically different

C. Generic drugs are chemically identical but lower priced

D. Brand-name drugs are available without prescriptions

9. In which step of selecting a PBM vendor does the phrase "Who is watching the watcher" apply?

A. Step 1

B. Step 2

C. Step 3

D. Step 4

10. Which of the following is not a step in the RFP process?

A. Preparation of scope of services

B. Submission to local government

C. Review of proposals by supply chain staff

D. Interview and evaluation process

SAMPLE

Answers

SAMPLE

1. B
2. A
3. B
4. C
5. A
6. C
7. B
8. C
9. B
10. B

SAMPLE

Explanations

SAMPLE

1. What is the role of a rebate aggregator?

A. To distribute drugs to pharmacies

B. To manage manufacturer rebate contracts

C. To adjudicate patient claims

D. To create formulary lists

The role of a rebate aggregator primarily involves managing manufacturer rebate contracts. Rebate aggregators act as intermediaries between pharmaceutical manufacturers and pharmacy benefits managers (PBMs) or payers. Their function includes negotiating, collecting, and distributing rebates that manufacturers offer to PBMs based on specific formulary placement or sales performance metrics. By managing these contracts, rebate aggregators help streamline the process, ensuring that PBMs can optimize their rebates and negotiate better deals with manufacturers. This process ultimately impacts drug pricing and access for patients, as the savings from rebates can be reflected in reduced costs for the drugs prescribed. The other options, while related to the pharmaceutical and healthcare supply chain, pertain to different functions. Distributing drugs to pharmacies is typically the role of wholesalers or pharmaceutical distributors. Adjudicating patient claims is generally handled by PBMs or insurance companies when they process claims for medication coverage. Creating formulary lists involves selecting which drugs are covered under a specific plan and is usually a task for PBMs or health plan administrators, rather than rebate aggregators.

2. What classification of Drug Utilization Review (DUR) evaluates a patient's drug therapy before medication is dispensed?

A. Prospective

B. Concurrent

C. Retrospective

D. Introspective

The classification of Drug Utilization Review (DUR) that evaluates a patient's drug therapy before medication is dispensed is prospective DUR. This type of review is conducted prior to the dispensing of a medication and involves assessing various factors, such as potential drug interactions, allergies, and appropriateness of the prescribed therapy based on the patient's history and current medications. The objective is to prevent adverse drug events and ensure the safety and effectiveness of the therapy before the medication reaches the patient. In contrast, concurrent DUR occurs during the course of therapy, allowing for monitoring and adjustments as a patient is actively taking medications. Retrospective DUR, on the other hand, involves reviewing medication use after the fact, examining records and clinical outcomes to identify patterns or issues that may have occurred during treatment. Introspective is not a standard classification within the context of DUR and does not pertain specifically to the evaluation of drug therapy.

SAMPLE

3. What term describes the complete elimination of hidden cash flows and full disclosure of service revenues?

A. Pass-through

B. Transparency

C. Fiduciary

D. Non-disclosure

The term that describes the complete elimination of hidden cash flows and the full disclosure of service revenues is transparency. In the context of financial reporting and service disclosures, transparency refers to the clarity and openness with which organizations communicate their financial activities and revenue streams. This principle is essential as it fosters trust between stakeholders, including patients, healthcare providers, and payers. By ensuring that all cash flows are visible and clearly articulated, transparency helps stakeholders make informed decisions based on comprehensive financial data. This concept is particularly important in healthcare and pharmacy benefits, where stakeholders must understand the financial implications of the services provided and the costs associated with them. Transparency helps mitigate risks associated with hidden costs or unclear financial practices that could mislead involved parties. Focusing on the other options, the pass-through model typically pertains to situations where a third party facilitates transactions without altering the costs. The fiduciary term relates to a responsibility to act in another party's best interest, emphasizing ethics and trust but not directly to the financial disclosure context. Non-disclosure, conversely, refers to the withholding of information, clearly in opposition to the idea of transparency. Therefore, recognizing transparency as the correct answer underscores its crucial role in maintaining integrity and trust in financial practices.

4. How does the Affordable Care Act influence pharmacy benefits?

A. It eliminates drug coverage requirements

B. It mandates coverage for preventive medications only

C. It requires health plans to provide essential health benefits

D. It reduces costs for brand-name drugs

The influence of the Affordable Care Act (ACA) on pharmacy benefits is primarily highlighted by the requirement for health plans to provide essential health benefits, which includes coverage for prescription drugs. This mandates that health insurance plans cover a defined set of health services, ensuring that pharmaceuticals are included, thereby improving access to necessary medications for patients. By establishing these essential health benefits, the ACA seeks to create a more comprehensive approach to healthcare, ensuring that pharmacy benefits are not only available but are also equitable across various health plans. This is critical in enhancing patient outcomes and supporting public health initiatives by ensuring that those insured have access to the medications that they need without excessive out-of-pocket expenses. Other options, such as reducing costs for brand-name drugs or limiting coverage to preventive medications, do not accurately reflect the provisions of the ACA. Additionally, the act does not eliminate drug coverage requirements but instead reinforces the necessity of including them as part of health insurance offerings. This comprehensive coverage is vital for managing chronic conditions and ensuring overall public health.

SAMPLE

5. What is a "spread" in the context of Pharmacy Benefit Managers?

A. The difference between PBM buying price and selling price

B. The total cost of prescription drugs

C. The discount offered by pharmacies to PBMs

D. The rebate amount from drug manufacturers

In the context of Pharmacy Benefit Managers (PBMs), a "spread" refers to the difference between the price at which PBMs purchase prescription drugs and the price at which they sell those drugs to health plans or network pharmacies. This difference can represent the revenue that PBMs generate from their activities. The spread can have significant implications for the overall cost of prescription drugs within a health plan, as it effectively creates a markup that is reflected in the pricing provided to payers. Understanding this concept is crucial for recognizing how PBMs operate and the financial flows involved in the purchasing and dispensing of medications. The spread can impact how much patients pay for their medications, particularly if the PBM retains a portion of the savings from negotiated discounts. The other options focus on different aspects of drug pricing and rebates, but do not accurately define what a "spread" is in relation to PBMs. The total cost of prescription drugs encompasses more than just the buying and selling prices, discounts reflect distinct negotiations between pharmacies and PBMs, and rebates specifically relate to incentives from drug manufacturers rather than the pricing mechanism within the PBM system itself.

6. What type of cancer is Gleevec used to treat?

A. Prostate Cancer

B. Multiple Myeloma

C. Leukemia and Other Types of Cancer

D. Rheumatoid Arthritis

Gleevec, known generically as imatinib, is primarily used to treat certain types of cancer, most notably chronic myeloid leukemia (CML) and gastrointestinal stromal tumors (GISTs). It functions as a targeted therapy, inhibiting specific proteins that drive the growth of cancer cells. Chronic myeloid leukemia is characterized by the presence of the Philadelphia chromosome, which results in the production of the BCR-ABL fusion protein. Gleevec effectively targets this protein, leading to significant improvements in patient outcomes. Additionally, the drug is effective against other conditions, including some forms of acute lymphoblastic leukemia (ALL) and other cancers that express the same or similar mutations. In contrast, other choices such as prostate cancer, multiple myeloma, and rheumatoid arthritis do not align with Gleevec's therapeutic indications. Prostate cancer is typically treated with hormone therapies, chemotherapy, or radiation. Multiple myeloma treatment involves different classes of medications, including proteasome inhibitors and immunomodulatory drugs, rather than Gleevec. Rheumatoid arthritis, an autoimmune condition, is generally managed with disease-modifying antirheumatic drugs (DMARDs), rather than oncology-targeted therapies like imatinib. Thus

SAMPLE

7. Which contracts are the most common pricing arrangements for PBMs with clients?

A. Capitated Contracts

B. Fee-For-Service Contracts

C. Shared Savings Contracts

D. Comprehensive Contracts

Fee-for-service contracts are indeed the most common pricing arrangements for Pharmacy Benefit Managers (PBMs) with their clients. In these agreements, the PBMs charge a fee for each service they provide, such as processing claims or managing pharmacy networks. This model allows clients, such as employers or health plans, to pay only for the services they actually use, making the costs more transparent and predictable. This approach is particularly appealing to clients because it aligns the PBMs' remuneration directly with the number of services rendered, encouraging efficiency and accountability. The fee-for-service structure also allows PBMs to offer a broader range of services and to customize their offerings to better meet the needs of different clients. In contrast, other types of contracts, such as capitated or shared savings contracts, involve different risk-sharing models that may not provide the level of service granularity and direct cost correlation seen in fee-for-service arrangements. Comprehensive contracts could include a mix of both fees and other payment models, but they are less common than straightforward fee-for-service contracts in the current market landscape.

8. What is the main difference between generic and brand-name drugs?

A. Generic drugs are sold at higher prices

B. Brand-name drugs are chemically different

C. Generic drugs are chemically identical but lower priced

D. Brand-name drugs are available without prescriptions

The distinction between generic and brand-name drugs primarily lies in their chemical composition and pricing structure. Generic drugs are chemically identical to their brand-name counterparts, which means they contain the same active ingredients, dosage form, strength, and route of administration. This equivalency ensures that the generic version provides the same therapeutic effect as the brand-name drug. The pricing difference arises from the fact that generics do not carry the branding costs and marketing expenses associated with brand-name drugs. Once the patent on a brand-name drug expires, other manufacturers are allowed to produce the generic version, often leading to significantly lower prices for consumers and healthcare systems. In contrast, brand-name drugs are those that are marketed under a trademarked name and are typically more expensive due to the research, development, and advertising costs associated with bringing a new drug to market. Understanding this fundamental difference is crucial, as it highlights the benefits of generic drugs in terms of cost savings without compromising on safety, efficacy, or quality.

SAMPLE

9. In which step of selecting a PBM vendor does the phrase "Who is watching the watcher" apply?

A. Step 1

B. Step 2

C. Step 3

D. Step 4

The phrase "Who is watching the watcher" is most relevant in the second step of selecting a PBM (Pharmacy Benefit Manager) vendor, which typically involves the evaluation and oversight of the chosen vendor's performance and compliance. This step is critical because it reflects the need for accountability and ensures that the PBM is fulfilling its obligations effectively, providing the necessary services, and managing the benefits appropriately. In this stage, it is essential to monitor how the PBM operates, including its claims processing, formulary management, and cost control measures. The oversight mechanism typically involves establishing key performance indicators (KPIs) and regular reporting to ensure that the PBM's actions align with the intended goals of the pharmacy benefit program. Thus, the phrase emphasizes the importance of having a structure in place to supervise and assess the vendor's functionality, ensuring transparency and effectiveness in the management of pharmacy benefits.

10. Which of the following is not a step in the RFP process?

A. Preparation of scope of services

B. Submission to local government

C. Review of proposals by supply chain staff

D. Interview and evaluation process

The process of creating a Request for Proposal (RFP) involves several critical steps that help organizations effectively solicit bids from suppliers or service providers. One key aspect of the RFP process is the preparation of a detailed scope of services, which outlines the expectations and requirements that need to be met by potential bidders. Additionally, reviewing proposals submitted by suppliers or service providers is essential for evaluating options and making informed decisions. The interview and evaluation process further assists in assessing the suitability of candidates based on their proposals. Submission to local government is not typically considered a step in the RFP process itself. While certain projects may require governmental approval or oversight, the RFP process primarily focuses on the interaction between the organization and potential suppliers rather than involving local government as a standard step. Therefore, this option is correctly identified as not being part of the RFP process.

SAMPLE

Next Steps

Congratulations on reaching the final section of this guide. You've taken a meaningful step toward passing your certification exam and advancing your career.

As you continue preparing, remember that consistent practice, review, and self-reflection are key to success. Make time to revisit difficult topics, simulate exam conditions, and track your progress along the way.

If you need help, have suggestions, or want to share feedback, we'd love to hear from you. Reach out to our team at hello@examzify.com.

Or visit your dedicated course page for more study tools and resources:

https://pharmbenefitspecialist.examzify.com

We wish you the very best on your exam journey. You've got this!

SAMPLE